What are the main classes of cardiac medications and how are they differentiated by their therapeutic targets and mechanisms of action?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cardiac Medication Categories and Differentiation

Cardiac medications are organized into distinct therapeutic classes based on their primary mechanisms of action and therapeutic targets, with the major categories including neurohormonal antagonists (ACE inhibitors, ARBs, ARNi, beta-blockers, mineralocorticoid receptor antagonists), metabolic modulators (SGLT2 inhibitors), diuretics, vasodilators, antiarrhythmics, anticoagulants/antiplatelets, and inotropic agents. 1, 2, 3

Core Therapeutic Classes

Neurohormonal Antagonists

These medications target the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system, which are fundamental to cardiac remodeling and disease progression:

  • ACE Inhibitors: Block conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion while increasing bradykinin (a vasodilator). Examples include enalapril, lisinopril, and ramipril 4, 2, 3. They are differentiated by their renal elimination pathway, requiring dose adjustment in renal impairment 5.

  • Angiotensin Receptor Blockers (ARBs): Directly block angiotensin II receptors without affecting bradykinin metabolism, resulting in fewer side effects like cough. Examples include candesartan, losartan, and valsartan 4, 2, 3. The key differentiator from ACE inhibitors is the absence of bradykinin potentiation 5.

  • Angiotensin Receptor-Neprilysin Inhibitor (ARNi): Sacubitril/valsartan combines ARB activity with neprilysin inhibition, increasing natriuretic peptides and enhancing vasodilation beyond traditional RAAS blockade 1, 2, 3. This dual mechanism provides superior mortality reduction compared to ACE inhibitors alone in HFrEF 3.

  • Beta-Adrenergic Antagonists (Beta-Blockers): Block sympathetic nervous system effects on the heart, reducing heart rate, contractility, and myocardial oxygen demand. Trial-proven agents include bisoprolol, carvedilol, and metoprolol succinate 1, 2, 3. Differentiate between cardioselective (beta-1 selective like bisoprolol, metoprolol) versus non-selective agents (carvedilol also blocks alpha-1 receptors, providing additional vasodilation) 6.

  • Mineralocorticoid Receptor Antagonists (MRAs): Spironolactone and eplerenone block aldosterone receptors, preventing sodium retention and cardiac fibrosis 1, 2, 3. The key distinction is that eplerenone has greater selectivity for mineralocorticoid receptors, causing less gynecomastia 3.

Critical caveat: Combining ACE inhibitors, ARBs, and renin inhibitors simultaneously is contraindicated due to increased risk of hyperkalemia, hypotension, and renal dysfunction 7.

Metabolic Modulators

  • SGLT2 Inhibitors: Dapagliflozin and empagliflozin inhibit sodium-glucose cotransporter-2 in the proximal tubule, causing glycosuria and natriuresis. Their cardiac benefits extend beyond glucose lowering through mechanisms including reduced preload, improved myocardial energetics, and decreased inflammation 1, 2, 3. These are now Class 2a recommendations for HFrEF and HFmrEF, and even HFpEF 1.

Diuretics

Differentiated by their site of action in the nephron:

  • Loop Diuretics: Furosemide, torsemide, bumetanide act on the thick ascending limb of the loop of Henle, providing potent diuresis for volume overload 4, 2, 4. No mortality benefit exists between different loop diuretics 2.

  • Thiazide-Type Diuretics: Hydrochlorothiazide, chlorthalidone act on the distal convoluted tubule, used primarily for hypertension 7. Chlorthalidone has longer duration of action than HCTZ 7.

  • Aldosterone Inhibitors: Listed separately above as MRAs due to their neurohormonal effects beyond diuresis 4.

Key differentiation: Loop diuretics provide more potent diuresis for acute decompensation, while thiazides are preferred for chronic hypertension management 2, 7.

Vasodilators

Categorized by mechanism and route:

  • Nitrates: Nitroglycerin (sublingual, topical, oral) and isosorbide release nitric oxide, causing venous and arterial dilation 4. Used for angina relief and acute pulmonary edema 4.

  • Hydralazine: Direct arterial vasodilator, used in combination with nitrates particularly in African American patients with HFrEF 4, 3.

  • Calcium Channel Blockers: Divided into dihydropyridines (amlodipine, nifedipine - primarily vasodilate) versus non-dihydropyridines (diltiazem, verapamil - also reduce heart rate and contractility) 4, 7. Important caveat: Non-dihydropyridine calcium channel blockers are generally contraindicated in heart failure due to negative inotropic effects 8, 4.

Antiarrhythmic Agents

Classified by the Vaughan Williams system based on ion channel effects 9, 10:

  • Class I (Sodium Channel Blockers): Subdivided into Ia (quinidine, procainamide), Ib (lidocaine), and Ic (flecainide, propafenone). Class Ic agents are contraindicated in structural heart disease due to proarrhythmic risk 8, 10.

  • Class II (Beta-Blockers): Discussed above; safe and effective for ventricular arrhythmias 9.

  • Class III (Potassium Channel Blockers): Amiodarone and sotalol prolong repolarization. Amiodarone is the most commonly used due to efficacy despite lack of clear mortality benefit 9. Sotalol also has beta-blocking properties 9.

  • Class IV (Calcium Channel Blockers): Non-dihydropyridines for rate control in atrial fibrillation 9.

Digitalis has unique properties affecting AV nodal conduction and inotropy, used for symptom relief in heart failure and rate control in atrial fibrillation 8, 4. Target trough digoxin levels are approximately 0.5-0.9 ng/mL to minimize toxicity 8.

Anticoagulants and Antiplatelets

  • Aspirin: Irreversibly inhibits cyclooxygenase, preventing platelet aggregation. Used in coronary artery disease but not routinely in idiopathic dilated cardiomyopathy 8, 4, 11.

  • Warfarin: Vitamin K antagonist for atrial fibrillation and mechanical valves 4.

  • Clopidogrel: P2Y12 inhibitor, alternative when aspirin contraindicated 11.

Critical interaction: Combining antiplatelet and anticoagulant therapy should not be routine except for specific indications like acute coronary syndromes 8.

Inotropic Agents

  • IV Inotropes: Dobutamine, milrinone increase contractility for acute decompensated heart failure 4.

  • IV Natriuretic Peptides: Nesiritide mimics BNP for acute decompensation 4.

Drugs to Avoid or Use with Caution

NSAIDs and COX-2 inhibitors worsen heart failure through fluid retention and should be avoided 8, 4. Thiazolidinediones (glitazones) cause fluid retention and are contraindicated in heart failure 8. Most antiarrhythmics (except amiodarone and beta-blockers) are contraindicated in heart failure due to negative inotropic effects 4.

Key Drug Interactions

The most clinically significant interactions include 8:

  • Amiodarone increases digoxin levels approximately twofold
  • Loop diuretics cause hypokalemia, increasing digoxin toxicity
  • Combining ACE inhibitors/ARBs with MRAs increases hyperkalemia risk
  • Beta-blockers and non-dihydropyridine calcium channel blockers together cause excessive bradycardia

Practical Differentiation Strategy

By primary therapeutic target:

  • Afterload reduction: ACE inhibitors, ARBs, ARNi, hydralazine, dihydropyridine CCBs
  • Preload reduction: Diuretics, nitrates
  • Heart rate/rhythm control: Beta-blockers, digoxin, antiarrhythmics, non-dihydropyridine CCBs
  • Neurohormonal modulation: ACE inhibitors, ARBs, ARNi, beta-blockers, MRAs
  • Metabolic effects: SGLT2 inhibitors

By clinical indication:

  • HFrEF requires: ACE inhibitor/ARB/ARNi + beta-blocker + MRA + SGLT2 inhibitor as foundational therapy 1, 2, 3
  • Hypertension first-line: Thiazide diuretics, ACE inhibitors, ARBs, or long-acting dihydropyridine CCBs 7
  • Atrial fibrillation rate control: Beta-blockers, non-dihydropyridine CCBs, or digoxin 8, 9
  • Acute coronary syndrome: Aspirin, beta-blockers, ACE inhibitors, statins 11

References

Guideline

guidelines for treating heart failure.

Trends in Cardiovascular Medicine, 2025

Research

Clinical pharmacokinetics of vasodilators. Part I.

Clinical pharmacokinetics, 1998

Guideline

east meets west: bringing the esh 2023 hypertension guidelines into asia.

European journal of internal medicine, 2024

Research

Antiarrhythmic agents and proarrhythmia.

Critical care medicine, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.